Effect of Vitamin E supplementation on clinical outcomes and related hematological, biochemical, and oxidative stress parameters in 5 – 14-year-old children infected with dengue fever
Phase 4
Not yet recruiting
- Conditions
- Dengue fever
- Registration Number
- SLCTR/2023/007
- Lead Sponsor
- Dept of Paediatrics, Faculty of Medicine, University of Colombo in collaboration with IBMBB of University of Colombo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Minimum age 5 and Maximum age 14-years
Male or female
Admitted within 84 hours of onset of fever, with Dengue NS 1 antigen positive.
Exclusion Criteria
Any child with an underlying chronic illness such as cardiac, renal or hepatic disease or on any long term medications
A child who cannot swallow a gel capsule
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Vitamin E supplementation to dengue fever clinical outcomes in pediatric patients?
How does Vitamin E compare to standard-of-care treatments in managing dengue-related oxidative stress in children?
Are there specific biomarkers that predict response to Vitamin E in dengue virus-infected pediatric populations?
What adverse events are associated with high-dose Vitamin E in children with dengue fever and how are they managed?
What combination therapies involving Vitamin E show potential for improving dengue fever treatment in 5-14-year-olds?